Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: A phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6364-6372

  Baselga, José ^a   Mita, Alain C ^b   Schöffski, Patrick ^c   Dumez, Herlinde ^c   Rojo, Frederico ^d   Tabernero, Josep ^d   DiLea, Clifford ^e   Mietlowski, William ^e   Low, Christie ^e   Huang, Jerry ^e   Dugan, Margaret ^e   Parker, Kathryn ^e   Walk, Eric ^f   Van Oosterom, Allan ^c   Martinelli, Erika ^g   Takimoto, Chris H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e NOVARTIS PHARMA AG   (Switzerland)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL DECISION MAKING; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; IC 50; IN VITRO STUDY; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SKIN BIOPSY; SKIN DISEASE; SOLID TUMOR; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC AGENTS; DECISION MAKING; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MAXIMUM TOLERATED DOSE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PURINES; SKIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84869212712     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1499     Document Type: Article

References (23)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99. (Pubitemid 46606324)
3. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5(suppl 1):11-5. (Pubitemid 30225451)
4. Soria JC, Fayette J, Armand JP. Molecular targeting: targeting angiogenesis in solid tumors. Ann Oncol 2004;15(suppl 4):iv223-7. (Pubitemid 39585338)
5. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64. (Pubitemid 44157563)
6. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931-41. (Pubitemid 38924540)
7. Goldman CK, Kim J, Wong W, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33. (Pubitemid 23071308)
8. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein M, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30. (Pubitemid 27527914)
9. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48. (Pubitemid 30305093)
10. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006;17(suppl 7):vii109-14. (Pubitemid 43985191)
11. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-9. (Pubitemid 32808285)
12. Hainsworth JD, Spigel DR, Sosman JA, Burris HA 3rd, Farley C, Cucullu H, et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007;5:427-32. (Pubitemid 351219695)
13. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867-74.
14. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
15. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011;17:6304-12.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302. (Pubitemid 35266289)
18. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84. (Pubitemid 41095130)
19. Clark AJ. The mode of action of drugs on cells. London, England: Edward Arnold & Co; 1933.
20. Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956;11:379-93.
21. Furchgott RF. The use of beta-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In:Harper NJ, Simmonds AB, eds Advances in drug research. New York, NY: Academic Press; 1966. p. 21-55.
22. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Prac Oncol 2008;5:378-91. (Pubitemid 351958963)
23. Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res 2007;13:6545-8. (Pubitemid 350206786)